AbbVie Inc., the pharmaceutical unit that split off from Abbott Laboratories Inc. at the beginning of the year, hosted its first financial call with investors Jan. 30, using the opportunity to lay out 2013 sales and earnings guidance and to temper investor concerns about the company’s dependence on its top-selling drug, the tumor necrosis factor inhibitor Humira (adalimumab).
“If we look at our late-stage pipeline, we believe that pipeline has the ability to generate, on a conservative basis,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?